Ethicon Endo-Surgery to acquire SurgRx
Interventional device developer Ethicon Endo-Surgery has entered into a definitive agreement to acquire SurgRx, a developer of the EnSeal bipolar tissue sealing devices.
The Cincinnati-based Ethicon said the acquisition will provide with a new energy platform to complement its Harmonic line of ultrasonic medical devices that are used to perform open and laparoscopic procedures.
Terms of the agreement were not disclosed. The transaction is subject to customary clearances, including the Hart-Scott-Rodino Antitrust Improvements Act and similar regulations in other countries, according to the company.
SurgRx of Redwood City, Calif., said its EnSeal family of devices combines high compression and controlled energy delivery to create strong vessel seals. The EnSeal device, which was cleared by the FDA in 2003, seals vessels up to 7 mm in diameter.
The Cincinnati-based Ethicon said the acquisition will provide with a new energy platform to complement its Harmonic line of ultrasonic medical devices that are used to perform open and laparoscopic procedures.
Terms of the agreement were not disclosed. The transaction is subject to customary clearances, including the Hart-Scott-Rodino Antitrust Improvements Act and similar regulations in other countries, according to the company.
SurgRx of Redwood City, Calif., said its EnSeal family of devices combines high compression and controlled energy delivery to create strong vessel seals. The EnSeal device, which was cleared by the FDA in 2003, seals vessels up to 7 mm in diameter.